Krystal Biotech Q2 EPS Forecast Increased by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at William Blair increased their Q2 2025 earnings estimates for shares of Krystal Biotech in a research note issued to investors on Monday, November 4th. William Blair analyst S. Corwin now expects that the company will earn $1.59 per share for the quarter, up from their previous forecast of $1.33. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share. William Blair also issued estimates for Krystal Biotech’s FY2026 earnings at $4.91 EPS and FY2027 earnings at $8.39 EPS.

A number of other equities analysts also recently commented on KRYS. Citigroup upped their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday. Stifel Nicolaus increased their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday. Chardan Capital increased their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $197.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $183.09 on Thursday. The company has a market cap of $5.26 billion, a P/E ratio of 103.44 and a beta of 0.82. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34. The firm has a fifty day moving average of $181.39 and a two-hundred day moving average of $180.25.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm earned ($0.67) EPS. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its position in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after acquiring an additional 7,537 shares during the last quarter. Hood River Capital Management LLC boosted its position in shares of Krystal Biotech by 5.1% in the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock worth $95,694,000 after acquiring an additional 25,507 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after acquiring an additional 103,928 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Krystal Biotech by 11.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock worth $32,402,000 after acquiring an additional 18,021 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).